当前位置: X-MOL 学术Oncoimmunology › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
In the mix: the potential benefits of adding GM-CSF to CpG-B in the local treatment of patients with early-stage melanoma.
OncoImmunology ( IF 6.5 ) Pub Date : 2019-12-26 , DOI: 10.1080/2162402x.2019.1708066
Bas D Koster 1 , Tamarah D de Jong 2 , Mari F C M van den Hout 3 , Berbel J R Sluijter 4 , Ronald J C L M Vuylsteke 4 , Barbara G Molenkamp 4 , Saskia Vosslamber 2 , M Petrousjka van den Tol 4 , Alfons J M van den Eertwegh 1 , Tanja D de Gruijl 1
Affiliation  

Whereas TLR9 agonists are recognized as powerful stimulators of antitumor immunity, GM-CSF has had mixed reviews. In previously reported randomized trials we assessed the effects of local immune modulation in early-stage melanoma with CpG-B alone or with GM-CSF. Here we discuss the added value of GM-CSF and show sex-related differences.

中文翻译:

在组合中:在 CpG-B 中添加 GM-CSF 在早期黑色素瘤患者的局部治疗中的潜在益处。

尽管 TLR9 激动剂被认为是强大的抗肿瘤免疫刺激剂,但 GM-CSF 的评价褒贬不一。在之前报道的随机试验中,我们评估了局部免疫调节在早期黑色素瘤中单独使用 CpG-B 或使用 GM-CSF 的效果。在这里,我们讨论 GM-CSF 的附加值并显示与性别相关的差异。
更新日期:2019-12-26
down
wechat
bug